Tempus to Partner with UChicago in Using Data to Better Cancer Treatment

The University of Chicago will team up with Tempus, an initiative from Groupon’s founder, Eric Lefkofsky, to enhance breast cancer treatment. Tempus, which is based in Chicago, announced that it would look into data from approximately 1,000 breast cancer cases. This will help provide useful information to help doctors and researchers identify patterns to assist in predicting patients’ response to treatment. This analysis is expected to help provide better treatment in the future.According to a statement by Dr. OlufunmilayoOlopade, a professor of medicine and human genetics at the University of Chicago, there is no significantly available data about breast cancer patient. This is unfortunate since breast cancer is “among the most common types of cancer.” As such, physicians make treatment decisions without the aid of reliable genetic information.

He applauded the idea to collaborate with Tempus, citing his support the initiatives pursuit for building the leading “clinically annotated molecular data set” for dealing with breast cancer. Tempus utilizes machine learning as well as genomic sequencing that helps physicians in making personalized and timely treatment.This is the most recent of Tempus’ partnerships in months. Others include Northwestern University’s Robert H. Lurie Comprehensive Cancer Center, Rush University Medical Center, Mayo Clinic, the University of Michigan, and Penn Medicine.You can also visit : http://www.lefkofsky.com/about/ to learn more.

Tempus was started in 2015, with its headquarters at 600 W. in Chicago. Other ventures founded by Lekofsky are located here too. One of these is Lightbank, which is based on investing in disruptive technologies. Lekofsky is also the founder of Groupon, a web-based marketplace. Besides, he is the co-founder of Uptake Technologies, a renowned platform for predictive analytics for leading global industries.Other ventures he has founded are Mediaocean-an integrated media procurement technology, and Echoglobal Logistics, which is a tech-based firm dealing with transportation and logistics. He is also the founder of InnerWorkings, a global managed print and promotional solutions company.

One thought on “Tempus to Partner with UChicago in Using Data to Better Cancer Treatment

  1. Bioinformatics and interest in data in medical science makes the hope for more Innerworkings kind of effort to pay in the future. I see the need for http://www.eessayontime.com/ to also make the work in cancer treatment be very positive in terms of the research results done. To have more positive outcome, there has to be closer look at data really.

Leave a Reply

Your email address will not be published. Required fields are marked *